Clinical trials
Lundbeck Brings Potential New Biologic Treatment of Parkinson’s Disease into Clinical Development
H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first participant in a Phase I study with the compound Lu AF82422.
The Alzheimer's Research Revolution
By Gary Tong, MD, PhD
There’s a revolution underway in the Alzheimer’s research world. At the heart is a change in the way researchers and regulators define and stage the disease, and it might just lead to the breakthrough Alzheimer’s researchers, patients and families have been waiting for.
Lundbeck Starts Clinical Development of Potential New Treatment of Parkinson's Disease
H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson’s disease. The compound – Lu AF28996– is invented by Lundbeck and will now be studied in healthy volunteers as first part of its clinical development.
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Otsuka Pharmaceutical Company, Ltd. and Lundbeck announce third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type.